7UX Stock Chart & Stats
€0.01
€0.00(0.00%)
At close: 4:00 PM EDT
€0.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.03
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€7.47M
Enterprise Value€44.74M
Total Cash (Recent Filing)€32.51M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding798,380,100
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.42
Price to Sales (P/S)99.92
P/FCF Ratio-1.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free balance sheet limits interest obligations and refinancing exposure, giving Spago greater flexibility while it develops its oncology pipeline. This financial structure can help preserve strategic options and reduce downside from leverage as the company works toward commercial scale.
Losses Have NarrowedThe gradual narrowing of annual losses is a constructive operating trend, even though profitability remains far away. If maintained, better cost control could extend the company’s runway and improve the efficiency of future investment in its nanomedicine development programs.
Proprietary Oncology PlatformSpago is focused on proprietary nanomedicine candidates spanning cancer imaging and targeted radionuclide therapy. A differentiated platform aimed at improving diagnosis and treatment could support multiple development opportunities and create durable strategic value if clinical progress is achieved.
Bears Say
Minimal Declining RevenueExtremely limited and declining revenue shows that Spago has not yet achieved meaningful commercial scale. This leaves the company dependent on successful development and future commercialization of its candidates, while providing little operating leverage or internally generated support for ongoing activities.
Persistent Cash BurnContinually negative operating and free cash flow means the business is not self-funding and must continue financing development through available resources or future capital. Persistent cash burn can constrain strategic flexibility and raises the importance of achieving revenue scale before resources are depleted.
Shrinking Equity CushionThe substantial reduction in equity reflects sustained losses or capital structure changes and leaves a much smaller financial cushion than in earlier periods. Although leverage is absent, a shrinking equity base reduces resilience and increases the significance of future funding requirements.
7UX FAQ
What was Spago Nanomedical AB’s price range in the past 12 months?
Spago Nanomedical AB lowest stock price was <€0.01 and its highest was €0.03 in the past 12 months.
What is Spago Nanomedical AB’s market cap?
Spago Nanomedical AB’s market cap is €7.47M.
When is Spago Nanomedical AB’s upcoming earnings report date?
Spago Nanomedical AB’s upcoming earnings report date is Nov 05, 2026 which is in 12 days.
How were Spago Nanomedical AB’s earnings last quarter?
Spago Nanomedical AB released its earnings results on Aug 20, 2026. The company reported >-€0.001 earnings per share for the quarter.
Is Spago Nanomedical AB overvalued?
According to Wall Street analysts Spago Nanomedical AB’s price is currently Overvalued.
Does Spago Nanomedical AB pay dividends?
Spago Nanomedical AB does not currently pay dividends.
What is Spago Nanomedical AB’s EPS estimate?
Spago Nanomedical AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Spago Nanomedical AB have?
Spago Nanomedical AB has 798,380,100 shares outstanding.
What happened to Spago Nanomedical AB’s price movement after its last earnings report?
Spago Nanomedical AB reported an EPS of >-€0.001 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Spago Nanomedical AB?
Currently, no hedge funds are holding shares in DE:7UX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Spago Nanomedical AB
Operating primarily in Sweden, Spago Nanomedical AB (publ) is dedicated to pioneering nanomedicines for both the diagnosis and treatment of cancer. The company is actively pursuing two key projects: the SpagoPix initiative, centered on SN132D, a gadolinium-free MRI contrast agent developed for imaging breast and pancreatic cancers; and the Tumorad project, which is advancing SN201, a radionuclide therapy intended for managing advanced and metastatic forms of cancer. Originally established as Spago Imaging AB (publ), the company adopted its current name, Spago Nanomedical AB (publ), in May 2014. Founded in 1999, its base of operations is situated in Lund, Sweden.
Technical Analysis
Biovica International AB Class B
―
Xspray Pharma AB
―
Immunicum AB
―
Cantargia AB
―
FluoGuide A/S
―